Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCampbell, Bruce C V-
dc.contributor.authorMa, Henry-
dc.contributor.authorParsons, Mark W-
dc.contributor.authorChurilov, Leonid-
dc.contributor.authorYassi, Nawaf-
dc.contributor.authorKleinig, Timothy J-
dc.contributor.authorHsu, Chung Y-
dc.contributor.authorDewey, Helen M-
dc.contributor.authorButcher, Kenneth S-
dc.contributor.authorYan, Bernard-
dc.contributor.authorDesmond, Patricia M-
dc.contributor.authorWijeratne, Tissa-
dc.contributor.authorCurtze, Sami-
dc.contributor.authorBarber, P Alan-
dc.contributor.authorDe Silva, Deidre A-
dc.contributor.authorThijs, Vincent N-
dc.contributor.authorLevi, Christopher R-
dc.contributor.authorBladin, Christopher F-
dc.contributor.authorSharma, Gagan-
dc.contributor.authorBivard, Andrew-
dc.contributor.authorDonnan, Geoffrey A-
dc.contributor.authorDavis, Stephen M-
dc.identifier.citationJAMA Neurology 2020; online first: 2 Novemberen
dc.description.abstractIntravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hours after onset and with wake-up onset stroke selected using perfusion imaging mismatch. However, whether the benefit is consistent across the 4.5- to 6-hours, 6- to 9-hours, and wake-up stroke epochs is uncertain. To examine the association of reperfusion with reduced disability, including by onset-to-randomization time strata in the Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND) and Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) randomized clinical trials. Individual patient meta-analysis of randomized clinical trials performed from August 2001 to June 2018 with 3-month follow-up. Patients had acute ischemic stroke with 4.5-to 9-hours poststroke onset or with wake-up stroke were randomized to alteplase or placebo after perfusion mismatch imaging. Analysis began July 2019 and ended May 2020. Reperfusion was defined as more than 90% reduction in time to maximum of more than 6 seconds' lesion volume at 24- to 72-hour follow-up. Ordinal logistic regression adjusted for baseline age and National Institutes of Health Stroke Scale score was used to analyze functional improvement in day 90 modified Rankin Scale score overall, including a reperfusion × time-to-randomization multiplicative interaction term, and in the 4.5- to 6-hours, 6- to 9-hours, and wake-up time strata. Symptomatic hemorrhage was defined as large parenchymal hematoma with a National Institutes of Health Stroke Scale score increase of 4 points or more. Reperfusion was assessable in 270 of 295 patients (92%), 68 of 133 (51%) in the alteplase group, and 38 of 137 (28%) in the placebo reperfused group (P < .001). The median (interquartile range) age was 76 (66-81) years in the reperfusion group vs 74 (64.5-81.0) years in the group with no reperfusion. The median (interquartile range) baseline National Institutes of Health Stroke Scale score was 10 (7-15) in the reperfusion group vs 12 (8.0-17.5) in the no reperfusion group. Overall, reperfusion was associated with improved functional outcome (common odds ratio, 7.7; 95% CI, 4.6-12.8; P < .001). Reperfusion was associated with significantly improved functional outcome in each of the 4.5- to 6-hours, 6- to 9-hours, and wake-up time strata, with no evidence of association between time to randomization and beneficial effect of reperfusion (P = .63). Symptomatic hemorrhage, assessed in all 294 patients, occurred in 3 of 51 (5.9%) in the 4.5- to 6-hours group, 2 of 28 (7.1%) in the 6- to 9-hours group, and 4 of 73 (5.5%) in the wake-up stroke in patients treated with alteplase (Fisher P = .91). Strong benefits of reperfusion in all time strata without differential risk in symptomatic hemorrhage support the consistent treatment effect of alteplase in perfusion mismatch-selected patients throughout the 4.5- to 9-hours and wake-up stroke time window.en
dc.titleAssociation of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-Up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.en
dc.typeJournal Articleen
dc.identifier.journaltitleJAMA Neurologyen
dc.identifier.affiliationPopulation Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Priority Research Centre for Stroke and Brain Injury, John Hunter Hospital, University of Newcastle, Newcastle, Australiaen
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St Albans, Victoria, Australiaen
dc.identifier.affiliationAmbulance Victoria, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australiaen
dc.identifier.affiliationDepartment of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationDepartment of Medicine, School of Clinical Science, Monash University, Clayton, Victoria, Australiaen
dc.identifier.affiliationDepartment of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationPrince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, Australiaen
dc.identifier.affiliationDepartment of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australiaen
dc.identifier.affiliationNew South Wales and Maridulu Budyari Gumal, The Sydney Partnership for Health, Education Research and Enterprise (SPHERE), University of New South Wales, Sydney, Australiaen
dc.identifier.affiliationGraduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwanen
dc.identifier.affiliationDepartment of Neurology, Helsinki University Hospital, Helsinki, Finlanden
dc.identifier.affiliationDepartment of Medicine, University of Auckland, Auckland, New Zealanden
dc.identifier.affiliationDepartment of Neurology, Singapore General Hospital Campus, National Neuroscience Institute, Singaporeen
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 22, 2021

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.